Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Buys $49,338.24 in Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor purchased 22,026 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the purchase, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. This trade represents a 58.96 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Perspective Therapeutics Trading Down 4.4 %

NYSE:CATX opened at $1.96 on Friday. The company’s 50-day moving average is $2.82 and its two-hundred day moving average is $6.04. Perspective Therapeutics, Inc. has a 1-year low of $1.90 and a 1-year high of $19.05.

Analyst Ratings Changes

CATX has been the topic of several research analyst reports. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 26th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a report on Monday. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average target price of $14.44.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics in the fourth quarter valued at $33,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI lifted its position in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares during the last quarter. ProShare Advisors LLC boosted its stake in Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after buying an additional 5,011 shares during the period. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at about $51,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.